Advances in atopic dermatitis in 2015.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27931536.
- Also identified by DOI 10.1016/j.jaci.2016.10.004.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This review aims to highlight recently published articles on atopic dermatitis (AD). Updated are the insights into epidemiology, pathology, diagnostics, and therapy. Epidemiologic studies have revealed a positive correlation between AD and systemic conditions, such as rheumatoid arthritis, inflammatory bowel disease, and neonatal adiposity. Pathologic findings highlight the involvement of novel barrier factors (desmoplakin and claudin), novel immune cell subsets (pathogenic effector T<sub>H</sub>2 cells and group 2 innate lymphoid cells), and differential skewing of helper T cells (eg, T<sub>H</sub>17 dominance in Asians with AD). As diagnostics, noninvasive examinations of the transepidermal water loss of neonates, the density of epidermal Staphylococcus species, and the gut flora might prognosticate the onset of AD. As for therapy, various methods are proposed, including conventional (petrolatum and UV) and molecule-oriented regimens targeting Janus kinase, signal transducer and activator of transcription 3, extracellular signal-regulated kinase, sirtuin 1, or aryl hydrocarbon receptor.
Medical subject headings
- Arthritis, Rheumatoid
- Dermatitis, Atopic
- Inflammatory Bowel Diseases
- Obesity
- Staphylococcal Infections
- Staphylococcus
- Th2 Cells